Related Experiment Video
Updated: Jun 28, 2026
05:30
Trophoblast Cell Recovery from Angiogenesis-Tube Formation Assay for Differentiation Marker Expression Analysis
Published on: November 8, 2024
Gestational trophoblastic neoplasia: an update
Jacqueline M Morgan1, John R Lurain
1John I. Brewer Trophoblastic Disease Center, Northwestern University Feinberg School of Medicine, 250 East Superior Street, Suite 05-2168, Chicago, IL 60611, USA.
Current Oncology Reports
|October 22, 2008
Summary
Gestational trophoblastic neoplasia (GTN) is treatable with over 90% cure rates. Staging guides therapy, with single-agent chemotherapy for low-risk GTN and multiagent chemotherapy for high-risk GTN, ensuring high survival outcomes.
Area of Science:
- Gynecologic Oncology
- Medical Oncology
- Reproductive Endocrinology
Background:
- Gestational trophoblastic neoplasia (GTN) encompasses invasive mole, choriocarcinoma, and placental site trophoblastic tumors.
- Current treatment strategies achieve an overall cure rate exceeding 90% for GTN.
- Accurate staging is crucial for selecting effective and minimally toxic therapies.
Purpose of the Study:
- To outline the diagnostic and staging criteria for GTN.
- To detail the therapeutic approaches for different stages of GTN.
- To emphasize the importance of individualized treatment for optimizing patient outcomes.
Main Methods:
- Classification of GTN based on disease extent and World Health Organization (WHO) scoring.
- Delineation of treatment protocols for nonmetastatic (stage I) and low-risk metastatic (stages II-III, WHO score < 7) GTN.
- Description of treatment strategies for high-risk metastatic GTN (stage IV, WHO score ≥ 7), including multiagent chemotherapy, radiation, and surgery.
Main Results:
- Single-agent chemotherapy yields nearly 100% survival for stage I and low-risk metastatic GTN.
- Multiagent chemotherapy, potentially combined with adjuvant therapies, achieves 80-90% survival for high-risk metastatic GTN.
- Effective staging ensures appropriate treatment selection, maximizing cure rates and minimizing toxicity.
Conclusions:
- Gestational trophoblastic neoplasia is a highly curable malignancy with appropriate management.
- Risk stratification through staging and WHO scoring is essential for guiding treatment decisions.
- Tailored therapeutic strategies, ranging from single-agent to multiagent chemotherapy with adjuvant interventions, are effective in achieving high survival rates for GTN patients.
Related Concept Videos
01:07Teratogenicity
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...